Centre for Trans-Sahara Disease, Vaccine and Drug Research, Ibrahim Badamasi Babangida University, Lapai, Nigeria.
School of Laboratory Medicine and Medical Sciences, Department of Medical Biochemistry, University of KwaZulu-Natal, Durban, South Africa.
Chem Biol Drug Des. 2021 Sep;98(3):421-434. doi: 10.1111/cbdd.13865. Epub 2021 Jul 3.
Drug-resistant Mycobacterium tuberculosis poses a great threat to public health and remains one of the red-flag tagged infectious diseases, with the tendency of comorbidity with other disease conditions such as HIV/AIDS. This perhaps is responsible for redoubling of effort in tuberculosis research and continuous change in patient management to optimize the drug therapy. Aminoacyl-tRNA synthetases are essential enzymes in M. tuberculosis that catalyse the transfer of a particular amino acid to its corresponding specific tRNA to form an aminoacyl-tRNA. These enzymes are believed to be novel antibacterial, antifungal and antiparasitic drug targets because of their role in the process of protein translation. Therefore, their existence as a compliment of M. tuberculosis has attracted a lot of research interest with the aim of curbing the scourge and provide the most effective drug in the treatment of tuberculosis. This leads to the discovery of a pool of aminoacyl-tRNA synthetases with their essential inhibitors. This review seeks to articulate the current advances in the development of new TB drugs exhibiting novelty in their mode of action with specific emphasis on aminoacyl-tRNA synthetases as drug targets.
耐药结核分枝杆菌对公众健康构成巨大威胁，仍然是被标记为红色的传染病之一，并且有与 HIV/AIDS 等其他疾病合并的趋势。这也许是加倍努力进行结核病研究和不断改变患者管理以优化药物治疗的原因。氨酰-tRNA 合成酶是结核分枝杆菌中的必需酶，它催化将特定氨基酸转移到其相应的特定 tRNA 上，形成氨酰-tRNA。由于它们在蛋白质翻译过程中的作用，这些酶被认为是新型的抗菌、抗真菌和抗寄生虫药物靶点。因此，它们作为结核分枝杆菌的一种补充，引起了大量的研究兴趣，旨在遏制这一祸害，并为结核病治疗提供最有效的药物。这导致了大量氨酰-tRNA 合成酶及其必需抑制剂的发现。本综述旨在阐述新型结核病药物开发的最新进展，这些药物在作用模式上具有新颖性，特别强调氨酰-tRNA 合成酶作为药物靶点。
